Neuropathological spectrum of synucleinopathies
Top Cited Papers
- 4 September 2003
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 18 (S6) , 2-12
- https://doi.org/10.1002/mds.10557
Abstract
Synucleinopathies comprise a diverse group of neurodegenerative proteinopathies that share common pathological lesions composed of aggregates of conformational and posttranslational modifications of α‐synuclein in selected populations of neurons and glia. Abnormal filamentous aggregates of misfolded α‐synuclein protein are the major components of Lewy bodies, dystrophic (Lewy) neurites, and the Papp–Lantos filaments in oligodendroglia and neurons in multiple system atrophy linked to degeneration of affected brain regions. The synucleinopathies include (1) Lewy body disorders and dementia with Lewy bodies, (2) multiple system atrophy (MSA), and (3) Hallervorden–Spatz disease. (1) The pathological diagnosis of Lewy body disorders and dementia with Lewy bodies is established by validated consensus criteria based on semiquantitative assessment of subcortical and cortical Lewy bodies as their common hallmarks. They are accompanied by subcortical multisystem degeneration with neuronal loss and gliosis with or without Alzheimer pathologic state. Lewy bodies also occur in numerous other disorders, including pure autonomic failure, neuroaxonal dystrophies, and various amyloidoses and tauopathies. (2) Multiple system atrophy, a sporadic, adult‐onset degenerative movement disorder of unknown cause, is characterized by α‐synuclein–positive glial cytoplasmic and rare neuronal inclusions throughout the central nervous system associated with striatonigral degeneration, olivopontocerebellar atrophy, and involvement of medullar and spinal autonomic nuclei. (3) In neurodegeneration with brain iron accumulation type I, or Hallervorden–Spatz disease, α‐synuclein is present in axonal spheroids and glial and neuronal inclusions. While the identity of the major components of Lewy bodies suggests that a pathway leading from normal soluble to abnormal misfolded filamentous proteins is central for their pathogenesis, regardless of the primary disorder, there are conformational differences in α‐synuclein between neuronal and glial aggregates, showing nonuniform mapping for its epitopes. Despite several cellular and transgenic models, it is not clear whether inclusion body formation is an adaptive/neuroprotective or a pathogenic reaction/process generated in response to different, mostly undetermined, functional triggers linked to neurodegeneration. © 2003 Movement Disorder SocietyKeywords
This publication has 67 references indexed in Scilit:
- α-Synuclein is phosphorylated in synucleinopathy lesionsNature Cell Biology, 2002
- α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasomeFEBS Letters, 2001
- α-Synuclein and the Lewy body disordersCurrent Opinion in Neurology, 2001
- Alpha-synuclein and neurodegenerative diseasesNature Reviews Neuroscience, 2001
- SynucleinopathiesArchives of Neurology, 2001
- α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregationBrain Research, 2001
- Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as α-SynucleinopathiesPublished by Springer Nature ,2000
- Widespread Nitration of Pathological Inclusions in Neurodegenerative SynucleinopathiesThe American Journal of Pathology, 2000
- α-Synuclein Inclusions in Amygdala in the Brains of Patients with the Parkinsonism-Dementia Complex of GuamJournal of Neuropathology and Experimental Neurology, 2000
- Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformationProceedings of the National Academy of Sciences, 2000